← Back to headlines
Ultragenyx Receives FDA IND Clearance for UX016 in GNE Myopathy Treatment
Ultragenyx has announced that its investigational new drug (IND) application for UX016, intended for the treatment of GNE myopathy, has received clearance from the FDA.
30 Mar, 14:38 — 30 Mar, 14:38
Sources
Showing 1 of 1 sources
Related Stories
Severe Algae Bloom Threatens Israel’s Desalination Infrastructure and Water Supply
8h ago
Ig Nobel Prizes Awarded at First Ceremony Held Outside the United States
21h ago
Dutch Soil Scientist Wins Ig Nobel Prize for Underwear Burial Experiment
1d ago
Quirky Research on Urinals and Candy Stealing Wins Ig Nobel Prizes
1d ago